What’s the current market cap for Atea stock?

Atea (AVIR) has a market cap of $374M as of May 30, 2026.

What is the P/E ratio for Atea stock?

The price to earnings (P/E) ratio for Atea (AVIR) stock is 0 as of May 30, 2026.

Does Atea stock pay dividends?

No, Atea (AVIR) stock does not pay dividends to its shareholders as of May 30, 2026.

When is the next Atea dividend payment date?

Atea (AVIR) stock does not pay dividends to its shareholders.

What is the beta indicator for Atea?

Atea (AVIR) has a beta rating of 0.38. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy Atea stock | $AVIR Share Price

About Atea

Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.

Ticker

$AVIR

Sector

Health

Primary listing

NASDAQ

Employees

55

Headquarters

Boston, United States

Website

ateapharma.com

Atea Metrics

BasicAdvanced

$374m

-

-$2.12

0.38

-

What the Analysts think about Atea

Analyst ratings (Buy, Hold, Sell) for Atea stock.

Bulls say / Bears say

Atea has completed enrollment of more than 880 treatment-naïve patients in its North American C-BEYOND Phase 3 trial of bemnifosbuvir/ruzasvir, positioning it for topline results in mid-2026 ([Reuters]) ([sahmcapital.com])

Atea’s AT-587 demonstrated strong in vitro activity as a first-in-class HEV inhibitor at CROI 2026, with a Phase 1 program expected to start in mid-2026, expanding the antiviral portfolio beyond HCV ([Reuters]) ([tradingview.com])

The company presented a clear catalyst timeline for 2026: topline results from the C-BEYOND trial are expected in mid-2026, while the C-FORWARD ex-US trial will read out by year-end 2026, offering two near-term binary catalysts ([Reuters]) ([sahmcapital.com])

The HCV market is dominated by established direct-acting antivirals and faces strong pricing pressure, which makes it difficult for Atea’s regimen to gain market share ([Reuters]) ([ca.investing.com])

There is a risk that Atea’s Phase 3 bemnifosbuvir/ruzasvir regimen may not prove to be non-inferior to the current standard of care, which could weaken its clinical appeal ([Reuters]) ([ca.investing.com])

Atea’s AT-587 is still in preclinical development and Phase 1 trials will not start until mid-2026, delaying diversification and leaving the company heavily dependent on HCV trial results ([Reuters]) ([tradingview.com])

Data summarised monthly by Lightyear AI. Last updated on 6 May 2026.

Atea Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

Atea Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

Atea News

AllArticlesVideos

Atea Pharmaceuticals Q1 Earnings Call Highlights

MarketBeat·3 weeks ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

About Atea

Ticker

Employees

Atea Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

What the Analysts think about Atea

Analyst Ratings

Bulls say / Bears say

Atea Financial Performance

Income Statement

Atea Earnings Performance

Earnings per share (EPS)

Atea News

Atea Pharmaceuticals Q1 Earnings Call Highlights

Buy $AVIR

Upcoming events

No upcoming events

Lightyear

Legal

Work with us

Bulls say / Bears say

Atea/$AVIR

About Atea

Ticker

Employees

Atea Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

What the Analysts think about Atea

Analyst Ratings

Bulls say / Bears say

Atea Financial Performance

Income Statement

Atea Earnings Performance

Earnings per share (EPS)

Atea News

Atea Pharmaceuticals Q1 Earnings Call Highlights

Buy $AVIR

Upcoming events

No upcoming events

What’s the current market cap for Atea stock?

What is the P/E ratio for Atea stock?

Does Atea stock pay dividends?

When is the next Atea dividend payment date?

What is the beta indicator for Atea?

Bulls say / Bears say